andexanet alfa

Ligand id: 7576

Name: andexanet alfa

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: andexanet alfa

No information available.
Summary of Clinical Use
Patients receiving direct factor Xa inhibitor drugs to reduce thrombotic events may have bleeding crises, or may need urgent surgical intervention where the presence of anti-clotting drugs would be problematic. Andexanet alfa was designed to address these issues by effectively and rapidly removing the inhibitor drugs from the blood [4]. In vitro experiments show that andexanet alfa dose-dependently reverses the inhibitory activity of tested small-molecule FXa inhibitors, and in vivo studies show that andexanet alfa is able to restore hemostasis in a rats treated with FXa inhibitors or in a mouse model of blood loss [1].
Preliminary results of a Phase 2 clinical trial (NCT01758432) indicated that andexanet alfa rapidly reversed the action of rivaroxaban in human subjects.
In May 2018, the FDA approved andexanet alfa (Andexxa®) to reverse the anticoagulation effects of rivaroxaban and apixaban, in patients that are experiencing life-threatening or uncontrolled bleeding [3].
Mechanism Of Action and Pharmacodynamic Effects
Andexanet alfa acts as a decoy and binds to FXa inhibitors. It binds FXa inhibitor drugs more strongly than it does FXa itself [1]. In this way the recombinant peptide neutralizes the inhibitor drugs in the bloodstream and restores hemostasis.